CHF Solutions (Eden Prairie, Minn.) recently announced that it has entered a collaboration agreement with Daxor (New York) to explore synergies between CHF Solutions’s Aquadex FlexFlow System and Daxor’s BVA-100 Blood Volume Analyzer.
CHF Solutions suggests that the two technologies could be used together to measure a patient’s fluid volume status while also informing clinicians on clinical management of a fluid overloaded patient.
As part of the collaboration, a small clinical evaluation will be performed to evaluate the benefits of blood volume measurement and its potential to inform ultrafiltration therapy management using the Aquadex FlexFlow system. Prior evaluations show that 24% of fluid overloaded patients are readmitted to the hospital within 30 days and 50% are readmitted within six months.
“Daxor seeks to supply healthcare providers with the means to improve heart failure treatment outcomes. We feel that the combination of our precision diagnostic combined with Aquadex FlexFlow therapy for fluid overload may result in significantly improved patient care,” said Michael Feldschuh, CEO of Daxor Corporation. “We further believe that this relationship has tremendous potential to benefit patients and look forward to exploring the many benefits of working with CHF Solutions.”
The two companies hope that the BVA-100 will inform clinicians on fluid volume status, such as patient selection, when to start ultrafiltration therapy and how to manage therapy.
“We believe that ultrafiltration with the Aquadex FlexFlow system is an essential component to effectively manage fluid overloaded patients who have failed diuretics,” said John Erb, chairman and CEO of CHF Solutions, in a press release. “We believe that this collaboration with Daxor is another important building block of our strategy to evaluate diagnostic tools which may refine and maximize fluid management therapy.”
